[HTML][HTML] Coxibs and cardiovascular disease

GA FitzGerald - New England Journal of Medicine, 2004 - Mass Medical Soc
New England Journal of Medicine, 2004Mass Medical Soc
The coxibs are a subclass of nonsteroidal antiinflammatory drugs (NSAIDs) designed to
inhibit selectively cyclooxygenase-2 (COX-2). 1 Their development was based on the
hypothesis that COX-2 was the source of prostaglandins E2 and I2, which mediate
inflammation, and that cyclooxygenase-1 (COX-1) was the source of the same
prostaglandins in gastric epithelium, where they afford cytoprotection. Three coxibs—
celecoxib, rofecoxib, and valdecoxib—have been approved for use by the Food and Drug …
The coxibs are a subclass of nonsteroidal antiinflammatory drugs (NSAIDs) designed to inhibit selectively cyclooxygenase-2 (COX-2).1 Their development was based on the hypothesis that COX-2 was the source of prostaglandins E2 and I2, which mediate inflammation, and that cyclooxygenase-1 (COX-1) was the source of the same prostaglandins in gastric epithelium, where they afford cytoprotection. Three coxibs — celecoxib, rofecoxib, and valdecoxib — have been approved for use by the Food and Drug Administration (FDA); a fourth, etoricoxib, has been approved by the European regulatory authority, and it and a fifth, lumiracoxib, are currently under consideration for FDA . . .
The New England Journal Of Medicine